COVID-19 PPE joint venture
Company: CleanSpark
The claim, verbatim
Entered into joint venture with international partners to procure, distribute and supply masks, gowns, gloves and other PPE to hospitals and frontline medical personnel, with Company receiving $0.20 per unit sold and ability to reinvest capital for follow-on purchases
Source (primary)
CleanSpark 10-Q filed 2020-05-11 (SEC EDGAR, sec_filing)
View cached copy (2026-09-13)Live source ↗
Quote: “CleanSpark entered into a joint venture agreement with international partners to procure, distribute and supply masks, gowns, gloves, and other Personal Protective Equipment (PPE) to be supplied to hospitals and frontline medical personnel. In connection with its contribution of capital, the Company will receive $0.20 per unit sold through use of its funds, with the ability to re-invest the contributed capital for follow-on purchases at least four (4) times over”
How we checked this
Checked on September 23, 2026. The cited source supports every part of this claim.
The filing describes the April 2020 PPE joint venture and the company's $0.20-per-unit return. It also states the company may reinvest its capital for follow-on purchases at least four times over.
Confirmed in the source:
- CleanSpark entered into a joint venture with international partners to procure, distribute and supply masks, gowns, gloves and other PPE to hospitals and frontline medical personnel
- The company will receive $0.20 per unit sold through use of its funds
- The company can reinvest the contributed capital for follow-on purchases
What we did: Read our cached copy of SEC EDGAR (https://www.sec.gov/Archives/edgar/data/827876/000166357720000136/clsk10q.htm) in full (142,593 characters, retrieved September 13, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms CleanSpark 10-Q filed 2020-05-11
Quote: “CleanSpark entered into a joint venture agreement with international partners to procure, distribute and supply masks, gowns, gloves, and other Personal Protective Equipment (PPE) to be supplied to hospitals and frontline medical personnel. In connection with its contribution of capital, the Company will receive $0.20 per unit sold through use of its funds, with the ability to re-invest the contributed capital for follow-on purchases at least four (4) times over”